Semma Therapeutics nets $44 mln

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has secured $44 million in Series A funding. MPM Capital led the round with participation from Fidelity Biosciences, ARCH Venture Partners and Medtronic. Also, the company has named Stephen Oesterle, senior vice president for medicine and technology at Medtronic, as a board observer.

130 Views

Clinical Ink racks up venture funding, also merges with CentrosHealth

Clinical Ink, a provider of eSource solutions for clinical trials has raised an undisclosed amount of funding. The investors in this round included MPM Capital, F2 Ventures and FCA Venture Partners. In conjunction with the funding, MPM Capital and F2 Ventures will take seats on Clinical Ink’s board of directors. Also, Clinical Ink is merging with CentrosHealth, a provider of mobile apps for clinical trial patient engagement and electronic patient reported outcomes. No financial terms were disclosed. CentrosHealth was founded by MPM Capital.

Baeuerle joins MPM Capital as MD

MPM Capital said Wednesday it named Dr. Patrick A. Baeuerle a Managing Director effective April 1. Baeuerle most recently was Vice President, Research, and General Manager, Amgen Research (Munich) GmbH.

Vascular Pharmaceuticals snares $9 mln

Research Triangle Park, North Carolina-based Vascular Pharmaceuticals Inc, a diabetes-focused pharmaceutical company, has secured $9 million in Series A funding. The investors included Lumira Capital, Intersouth Partners and MPM Capital. In addition to the funding, Dr. Beni Rovinski, managing director of Lumira Capital, has been added to VPI’s board of directors.

113 Views

Chiasma snags $70 mln Series E

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.

VC-backed Raze Therapeutics names new VP

Raze Therapeutics has hired Dr. Mikel Moyer as vice president of molecular discovery. The appointment becomes effective November 1. Based in Cambridge, Mass., Raze Therapeutics is a biotech firm focused on developing new cancer drugs. Its backers include Atlas Venture, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management and Novartis.

Drone quadcopter released to monitor Indonesia's Mount Sinabung volcano. By  REUTERS/Beawiharta
165 Views

Top 10 posts: venture capital

Trending in VC deals this week: unmanned aerial vehicles (aka drones), wearable technology, mobile tech for online education, employee-scheduling software, tech talent development program and cloud security.

138 Views

VC-backed Rhythm files for IPO

Rhythm has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Citigroup and Cowen and Company are serving as the lead underwriters. Based in Boston, Rhythm is a biopharmaceutical firm that focuses on treating metabolic disorders. Its backers include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen and Pfizer Ventures.

Cerecor closes first tranche of $32 mln Series B

Cerecor has closed on the initial tranche of a $32 million Series B funding. New Enterprise Associates, Apple Tree Partners and MPM Capital led the round. Based in Baltimore, Cerecor is a biopharmaceutical firm focused on developing treatments for patients suffering from nervous system disorders.

True North Therapeutics bags $22 mln Series A

South San Francisco-based biotech firm True North Therapeutics has closed $22 million in Series A funding. The investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures and Baxter Ventures.

Proteon Therapeutics grabs $45 mln Series D

Proteon Therapeutics said Friday that it has raised $45 million in Series D financing. Abingworth led the round with participation from Deerfield Management Company, Pharmstandard International S.A., TVM Capital, Prism VentureWorks, Skyline Ventures, Intersouth Partners, MPM Capital, Devon Park Bioventures, Bessemer Venture Partners and the Vectis Healthcare and Life Sciences Fund. In addition to the funding, Tim Haines, a partner at Abingworth, and Dmitry Kobyzev, an investment manager at Inbio Ventures, have been added to Proteon Therapeutics’ board of directors. Headquartered in Waltham, Mass., Proteon Therapeutics is a biopharmaceutical firm focused on treating kidney and vascular diseases.

Iconic Therapeutics snags $20 mln

Iconic Therapeutics said Wednesday that it has closed $20 million in Series B-1 financing. The investors were MPM Capital, Lundbeckfond Ventures and H.I.G. BioVentures. In conjunction with the funding, Iconic has named MPM partner Dr. William Greene as CEO. Also, MPM’s Todd Foley, H.I.G’s Dr. Bruce Robertson and Dr. Johan Kordel of Lundbeckfond Ventures have been added to Iconic’s board of directors. Based in South San Francisco and Atlanta, Iconic is a biotech firm focused on serious eye disorders.

VC-backed Syndax Pharmaceuticals files for IPO

Syndax Pharmaceuticals has filed for an IPO. The number of shares that will be offered as well as the stock’s pricing terms have yet to be set. Deutsche Bank Securities and Jefferies are serving as lead underwriters. Headquartered in Waltham, Mass., Syndax is a Syndax Pharmaceuticals is a developer of epigenetic therapies for treatment-resistant cancers. Its backers include Domain Associates, MPM Capital, Forward Ventures, Pappas Ventures and Avalon Ventures.

112 Views

VC-backed TriVascular files for IPO

TriVascular Technologies has filed for an IPO. The number of shares that will be offered as well as its pricing terms have yet to be set. The stock will trade on the NASDAQ under the ticker symbol “TRIV.” J.P. Morgan Securities and Credit Suisse Securities are the lead underwriters. Based in Santa Rosa, Calif., TriVascular Technologies is a provider of endovascular aortic repair solutions. Its backers include NEA, Delphi Ventures, MPM Capital, Kearny Venture Partners, Kaiser Permanente Ventures, Rock Springs Capital and Permal Asset Management.

MPM Capital Takes Minority Stake in InformedDNA

MPM Capital has acquired a minority stake in InformedDNA, a US provider of genetic counseling and genetic benefits management services. The investment fr­om MPM’s SunStates Fund will be used to expand InformedDNA’s current genetic benefits utilization management offerings while also funding the development of new specialty genetic services for the pharmaceutical industry.

Epizyme Files for an IPO

Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.

23andMe Raises More Than $50M From Milner, NEA, Brin, Google, Others

23andMe, Inc. said it raised more than $50 million in a Series D financing with new investor Yuri Milner joined by existing investors Google co-founder Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. The company said the Series D investment, along with rapidly decreasing costs, allowed it to lower the price of its Personal Genome Service to $99,

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget